News

BirchBioMed Receives Health Canada Green Light to Start the Last Stage of its Groundbreaking Clinical Program of FS2 to Minimize Scarring from Burns

October 30, 2024

BirchBioMed Welcomes Dr. Carlos Roberto Camozzi as Chief Medical Officer

March 29, 2023

BirchBioMed Welcomes Hervé Girsault as Chief Business Officer

March 1, 2023

BirchBioMed Welcomes Dr. Jonathan Bourne as New Chief Science Officer

April 15, 2021

Innovation in Treatment of Keloid Scars

March 29, 2021

Positive Topline Data from Phase 2 Study of FS2 for Treatment of Keloid Scars

January 21, 2021

BirchBioMed Appoints Pharmaceutical Leader and Global Affairs Expert to its Board of Directors

November 4, 2020

BirchBioMed Welcomes Renowned Dermatologist to its Board of Directors

March 25, 2020

BirchBioMed Enrolls First Patient in Phase II Clinical Trial of its Unique Treatment to Prevent Scarring

December 9, 2019

BirchBioMed Issues Letter to Shareholders

March 28, 2019

First Patient Enrolled in BirchBioMed’s Study Investigating FS2 for the Treatment of Scars

February 28, 2019

BirchBioMed to Highlight FS2 Platform at the 17th Annual South Beach Symposium

February 5, 2019

BirchBioMed, Inc. to Present at the 11th Annual LD Micro Main Event

November 29, 2018

BirchBioMed, Inc. to Present at the 11th Annual LD Micro Main Event

November 29, 2018

Sensus Healthcare CEO Joseph C. Sardano Joins BirchBioMed Inc. Board of Directors

August 13, 2018

Chief Science Officer, Dr. Ryan Hartwell, Lecture at South Beach Symposium on the Latest Discoveries and Innovations in Fibrosis Research, Notably Highlighting Published Data from BirchBioMed and the University of British Columbia.

May 10, 2018

Q&A with Mark S. Miller, Co-founder, Chairman and CEO of BirchBioMed Inc. Developing an Antifibrotic Therapeutic for the Prevention of Scaring and Breaking Down Existing Scars and an Autoimmune Platform for Reversing Type l Diabetes

April 9, 2018

Chairman & CEO, Mark Miller Remarks Delivered at CEO Forum at South Beach Symposium on “Innovation in an Era of Healthcare Upheaval”

March 3, 2018

BirchBioMed is Cleared to Begin First-of-its-kind Phase II Clinical Trial for Ground-Breaking Anti-Scarring Drug

February 17, 2018

Sensus Healthcare Launches Collaboration with BirchBioMed to Treat and Prevent Scarring for Keloids Patients Around the World

February 5, 2018

BirchBioMed’s Scientific Advisory Board Member Dr. Aziz Ghahary is the 2017 British Columbia Professional Fire Fighters Burn Fund Honouree

July 25, 2017

BirchBioMed Announces Completion of Clinical Trial for Ground-breaking Anti-scarring Drug

August 25, 2016

UBC Develops Anti-scarring Drug

September 1, 2015

CKNW – Sean Leslie Show – Fibrostop, a Drug to Help Burn Victims

September 1, 2015

UBC Researchers Develop Drug to Treat Scarring and Autoimmune Diseases

August 28, 2015